Last year was a big year for Fairbanks Museum, highlighted by major moments in the museum’s 136-year history, but in 2025, the museum will focus on the smaller things, both literally and ...

The 26-year-old was originally slated to fight the Japanese boxing megastar on Christmas Eve but suffered a cut above his left eye. UFC 311: MAKHACHEV VS TSARUKYAN 2 | SUN 20 JAN | Order Now with ...

The investigational oral therapies DNL343 and fosigotifator didn’t significantly slow disease progression in people with amyotrophic lateral sclerosis (ALS) compared with a placebo, and therefore ...

The experimental drug, fosigotifator, was tested as a potential treatment for amyotrophic lateral sclerosis (ALS). This deadly neurodegenerative disease affects the nerve cells in the brain and ...

The Californian firm has revealed disappointing initial top-line results from Regimen F of the HEALEY ALS Platform Trial evaluating fosigotifator (ABBV-CLS-7262) in adults with amyotrophic lateral ...

Researchers at the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital said fosigotifator, the investigational drug being developed by Calico Life Sciences in collaboration with ...

Massachusetts General Hospital found neither AbbVie and Calico’s fosigotifator nor Denali’s DNL343 significantly slowed disease progression, causing misses on their respective primary endpoints.

Calico's drug, called fosigotifator, is one of a handful run through a clinical trial platform at Massachusetts General Hospital, which disclosed fosigotifator's topline study results Monday.

Fosigotifator, an amyotrophic lateral sclerosis drug developed by Calico Life Sciences, a biotech company backed by Google's parent company Alphabet, failed to meet its primary endpoint ...

(Cell Reports) Topline results from a HEALEY platform trial showed that fosigotifator, an investigational eIF2B activator developed by the longevity company Calico Life Sciences in collaboration ...